Interleukin-6 is a major effector molecule of short-term G-CSF treatment inducing bone metabolism and an acute-phase response
- 1 July 2001
- journal article
- Published by Elsevier in Experimental Hematology
- Vol. 29 (7) , 812-821
- https://doi.org/10.1016/s0301-472x(01)00656-7
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- Acute-Phase Proteins and Other Systemic Responses to InflammationNew England Journal of Medicine, 1999
- IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses.Journal of Clinical Investigation, 1998
- Interleukin (IL)-6 Directs the Differentiation of IL-4–producing CD4+ T CellsThe Journal of Experimental Medicine, 1997
- Osteoporosis in severe congenital neutropenia treated with granulocyte colony‐stimulating factorBritish Journal of Haematology, 1995
- Differential expression of cell adhesion molecules by human hematopoietic progenitor cells from bone marrow and mobilized adult peripheral bloodThe International Journal of Cell Cloning, 1995
- Impaired immune and acute-phase responses in interleukin-6-deficient miceNature, 1994
- Antiinflammatory properties of hepatic acute phase proteins: preferential induction of interleukin 1 (IL-1) receptor antagonist over IL-1 beta synthesis by human peripheral blood mononuclear cells.The Journal of Experimental Medicine, 1993
- Kinetics of circulating haematopoietic progenitors during chemotherapy‐induced mobilization with or without granulocyte colony‐stimulating factorBritish Journal of Haematology, 1993
- Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating FactorNew England Journal of Medicine, 1992
- Increased Osteoclast Development After Estrogen Loss: Mediation by Interleukin-6Science, 1992